Regulus Q1 net loss $8.5M; cash $107.7M; RGLS8429 cohort 4 dosed

Regulus Therapeutics Inc.

2024-Q1 EPS reported -$0.29

Net loss of $8.5M ($0.29/shr) vs $7.1M ($0.42/shr) in Q1 2023.
Cash, equivalents & investments $107.7M at Mar 31, 2024; runway into H1 2026.
Initiated 4th & final cohort of Phase 1b MAD trial for RGLS8429 in ADPKD; topline from cohort 3 expected mid-2024.
Closed oversubscribed $100M private placement in Mar 2024 with new and existing institutional investors.
R&D expense $6.0M (up 22% YoY); G&A expense $2.8M (up 17% YoY).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Regulus Therapeutics Inc. reported the first quarter ended March 31, 2024 results: net income $8.5 million, or $0.29 per share (basic and diluted), EPS $0.29 per share (basic and diluted).

Period: the first quarter ended March 31, 2024
Net income: $8.5 million, or $0.29 per share (basic and diluted)
EPS: $0.29 per share (basic and diluted)
Result: reported results

Exact text from the filing

Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-135281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.